JAZZ vs PATH · P/E 1988, rev $4.07B vs P/E 19, rev $1.61B
Jazz Pharmaceuticals PLC (JAZZ) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the JAZZ and PATH stock pages for the full models.
Not investment advice.